Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of LVGN6051 Combined With Toripalimab and Paclitaxel for Recurrent/Metastatic HNSCC Rapidly Progressed From Previous Platinum-containing Curative Treatment or Contraindicated for Platinum-containing Treatment

NCT06378177 is registered in ClinicalTrials.gov with Lyvgen Biopharma Holdings Limited as lead sponsor.

NCT NCT06378177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06378177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of LVGN6051 Combined With Toripalimab and Paclitaxel for Recurrent/Metastatic HNSCC Rapidly Progressed From Previous Platinum-containing Curative Treatment or Contraindicated for Platinum-containing Treatment
Lead sponsor
Lyvgen Biopharma Holdings Limited
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 21, 2024
Completion date
October 31, 2027
Enrollment
64 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma